Acromegaly is a rare disease caused by excessive Growth Hormone (GH) secretion. It is usually diagnosed in adults aged 30 to 50, although can affect people at any age, and is characterised by allowing bones and tissue to grow more quickly, as well as a wide range of other symptoms.[ii] Neuroendocrine tumours (NETs) are rare tumours that can appear anywhere in the neuroendocrine system, the system that controls hormones.[iii] When a NET is in the gastroenteropancreatic (GEP) system (digestive tract or pancreas) it is known as a GEP-NET.[iv]
'It is through our successful partnerships with regulators, manufacturers and distributors across the region that today's news has been made possible. We're proud to announce the launch of this medicine in the Nordics today and look forward to expanding this to other countries across
'This launch is the first of what we hope will be many, as we continue to expand into the complex and value-added medicines space, to the benefit of healthcare professionals and patients in
About MYRELEZ (lanreotide) Lanreotide is indicated for:1
The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment.
The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.
The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.
About
With its European network and its expertise in the anti-infectives and endocrinology therapy areas,
Contact:
Jersey
JE4 0QH
T: +44 (0) 208 588 9100
Corporate Headquarters
Capital House
EC4N 7BL
T: +44 (0) 208 588 9100
Fax: +44 (0) 208 588 9200
E: enquiries@advanzpharma.com
(C) 2021 Electronic News Publishing, source